Home > Rheumatology > EULAR 2018 > Rheumatoid Arthritis > No Significant Differences When Tapering TNF Blockers Versus csDMARDs

No Significant Differences When Tapering TNF Blockers Versus csDMARDs

Presented By
Dr Van Mulligen, Erasmus MC, the Netherlands
EULAR 2018

Tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or anti-tumour necrosis factor (TNF) showed no significant differences in flare ratios, disease activity, functional ability, and quality of life (QoL) between both tapering strategies during the first 12 months of follow-up. Early detection of RA, early initiation of ‘intensive’ therapy, and a treat-to-target (T2T) approach have led to substantial improvements in clinical and radiographic outcomes in RA over the last two decades. This has resulted in 50% to 60% of early RA patients achieving sustained remission during the first year of follow-up. Although current guidelines recommend to consider tapering treatment, an optimal approach to gradually de-escalate csDMARDs or bDMARDs is still lacking substantial evidence.

Van Mulligen et al. aimed to evaluate the effectiveness of two tapering strategies: gradual tapering of csDMARDs and TNF therapy during one year of follow-up.[8] This study was s...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on